남자호르몬 INCHEON, KOREA--( / )--Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States (US), Canada, Europe, Japan, and Australia. SB11, a biosimilar candidate referencing LUCENTIS®[ii] (ranibizumab), is undergoing phase 3 clinical trial, while SB15, a biosimilar candidate referencing EYLEA®[iii] (aflibercept), is in pre-clinical development.
In addition, the agreement provides Biogen an option to extend the commercialization term for Samsung Bioepis’ three anti-TNF biosimilars - BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) - in Europe for additional five years, extending the original ten-year agreement.[1] BENEPALI™ is the most prescribed etanercept in France, Germany, Italy, Spain, and the United Kingdom (UK).[iv] IMRALDI™ is the leading adalimumab biosimilar in Europe.[iv]
The agreement also provides Biogen an option to receive commercialization rights to BENEPALI™, FLIXABI™ and IMRALDI™ in China in exchange for royalties on sales in the market.
The agreement is a testament to Samsung Bioepis’ strong track record in the field of biosimilars and the potential value that Samsung Bioepis’ ophthalmology biosimilars could deliver to patients and healthcare systems across the world. Under the agreement, Samsung Bioepis will receive upfront payments of USD 100 million, up to USD 270 million in milestone/option payments, as well as sharing of sales revenue. Samsung Bioepis will be responsible for development, regulatory registration, and manufacture of the products, while Biogen will be responsible for commercialization.
“In Europe, we have been very pleased with Biogen’s commercialization efforts with our anti-TNF medicines, fulfilling the mission of expanding access to high-quality medicines to patients across Europe. By building on this collaboration, we are excited to potentially expand the opportunity for patients living with ophthalmological conditions, who don’t have access to life-changing medicines,” said Christopher Hansung Ko, President and Chief Executive Officer, Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening their availability for patients and healthcare systems across the world.”
Samsung Bioepis’ products are now available across Europe, North America, Asia, Oceania, and Latin America. The company currently has four biosimilars approved and marketed across Europe, which include the anti-TNF trio of BENEPALI™ (etanercept), FLIXABI™ (infliximab) and IMRALDI™ (adalimumab), as well as an oncologic biosimilar, ONTRUZANT® (trastuzumab). In the United States, the company has one biosimilar - RENFLEXIS® (infliximab-abda) - approved and marketed. ONTRUZANT® (trastuzumab-dttb) received approval from the U.S. Food and Drug Administration (FDA) in January 2019, while ETICOVO™ (etanercept-ykro) and HADLIMA™ (adalimumab-bwwd) received FDA approval in April and July 2019, respectively.
[1] The effective dates of commercialization differ for each anti-TNF product based on the launch dates. BENEPALI™ and FLIXABI™ were launched in Europe in January and May 2016, respectively, while IMRALDI™ was launched in October 2018 in Europe.
About BENEPALI™ (etanercept)
BENEPALI™ (etanercept), a biosimilar referencing ENBREL®[v], was approved by the European Commission (EC) in January 2016 for the treatment of adults with moderate to severe rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) and plaque psoriasis, pediatric plaque psoriasis. BENEPALI™ is currently available in 25 countries in Europe and is the most prescribed etanercept in France, Germany, Italy, Spain and the United Kingdom.[iv]
About FLIXABI™ (infliximab)
FLIXABI™ (infliximab), a biosimilar referencing REMICADE®[vi], was approved by the European Commission (EC) in May 2016 for the treatment of adults with rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis or psoriasis. FLIXABI™ can also be used in patients 6-17 years old with severe, active Crohn’s disease or severely active ulcerative colitis when they have not responded to or cannot take other medicines or treatments. FLIXABI™ is currently available in 17 countries in Europe.[iv]
About IMRALDI™ (adalimumab)
IMRALDI™ (adalimumab), a biosimilar referencing HUMIRA®[vii], was approved by the European Commission (EC) in August 2017 for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, hidradenitis suppurativa, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, uveitis, and pediatric uveitis. IMRALDI™ is currently available in 19 countries in Europe and is the leading adalimumab biosimilar in Germany and in Europe year to date 2019.[iv, viii]
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: and follow us on social media - Twitter, LinkedIn.
[i] Data on file: Biogen, Inc. Third Quarter 2019 Financial Results and Business Update, Oct 22, 2019
[ii] LUCENTIS® is a registered trademark of Genentech
[iii] EYLEA® is a registered trademark of Regeneron Pharmaceuticals
[iv] Data on File: IQVIA, GERS, Insight Health ODV
[v] ENBREL® is a registered trademark of Pfizer/Amgen
[vi] REMICADE® is a registered trademark of Janssen
[vii] HUMIRA® is a registered trademark of AbbVie
[viii] Data on File: Biogen data on file
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
SAN FRANCISCO--( / )--Andersen Global announced a collaboration agreement with Szabo Kelemen & Partners Attorneys, 창인동홀덤펍 융통성 a respected law 창인동홀덤펍 firm based in Budapest, Hungary. Hungary marks the 38th country in which Andersen Global offers legal services, expanding the international association’s 창인동홀덤펍 실시간프로토베팅 growing presence in Eastern Europe. 노래주점아르바이트 싸커라인 Andersen Global is now present in more than 46 countries worldwide.
Founded over two decades ago, Szabo Kelemen & Partners began as mfQtSfr Foundedlegal arm of 노래주점아르바이트 남규리노래 EY in Hungary. The firm has since grown to be 노래주점아르바이트 프로토배당률 the premier law firm in Budapest. The team is comprised of more than 30 professionals with decades of 노래주점아르바이트 legal experience and international accolades, and will continue to advise 창인동홀덤펍 남규리섹시 local and international clients on tax, corporate and commercial issues in various industries.
“We started as part of the Big Four, and 주현동홀덤펍 “Wethe last several years, as we’ve watched Andersen Global grow and 노래주점아르바이트 남자모델 set the client service bar higher, it was fitting and natural 창인동홀덤펍 that we join forces to provide our clients with the very best, seamless service across the globe,” said Tamas Szabo, Founder and Managing Partner at Szabo Kelemen. “We look forward to working closely 창인동홀덤펍 올림픽중계 with our fellow collaborating firm in Budapest, OrienTax, as 노래주점아르바이트 배구중계 well as all the Andersen Global member and collaborating firms worldwide, to bring the very best service and solutions to clients.”
“Tamas and 노래주점아르바이트 니콜lost his 노래주점아르바이트 프로야구중계 team bring the type of expertise, professionalism and dedication that makes others stand up and notice,” said Mark Vorsatz, Andersen Global Chairman and Andersen Tax LLC 창인동홀덤펍 CEO. “We are continuing to expand our capabilities in this 노래주점아르바이트 region with the objective of becoming the standout legal and tax practice in the area. The combination of Szabo Kelemen & Partners and OrienTax make a very 중계본동화투치기 “Tamasand competitive platform for Andersen Global in Hungary.”
Andersen Global is an international association of legally separate, independent member firms comprised of tax and 우이동홀덤대회 Andersenprofessionals around the world. Established in 노래주점아르바이트 페이스북섹시버전 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has 창인동홀덤펍 over 4,000 professionals worldwide and a presence in over 129 locations through its member firms and collaborating firms.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through 창인동홀덤펍 라이브스코어 라이브맨 the 노래주점아르바이트 여자과외 industry’s largest press release distribution network
한진중공업주식,야플티비,헬븐넷,서울툰,짱툰,야동파일,정선,폭시에브,19사이즈,인스티즈,홀덤천국,섹스모임,남포동노래주점,주소체크
